IMMUNOME INC
IMNMNASDAQTrading Snapshot
- Day Range
- $26.24 – $26.63
- 52-Week Range
- $8.67 – $27.65
- Volume
- $3.54B
- Avg Volume
- $2.36B
- Shares Outstanding
- 113.3M
- Next Earnings
- Sep 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 231.1x
- EPS (TTM)
- $-2.36
- Dividend Yield
- —
Why Investors Own IMNM
- ✓High-growth profile — revenue up +39.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About IMMUNOME INC
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
The BioRevolution Has Accelerated
WisdomTree BioRevolution Fund delivered a dramatic acceleration in performance over S&P 500 Index, thereby drawing attention to this particular investment theme. Read more here.
SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
BOTHELL, Wash., July 20, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing advanced solid tumors.